Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Autophagy-related gene (ATG) messenger RNAs are the transcript products of a conserved set of genes that regulate the process of macroautophagy, a lysosomal degradation pathway essential for maintaining cellular homeostasis (Klionsky, D. J., et al., Developmental Cell, 2003). These mRNAs encode proteins that form functional complexes, such as the ULK1 initiation complex and the ATG12-ATG5-ATG16L1 conjugation system, which are vital for the nucleation and expansion of the autophagosome (Mizushima, N., & Komatsu, M., Cell, 2011). In the context of disease, ATG mRNAs are often dysregulated; for instance, their upregulation in certain cancers can promote tumor survival and resistance to chemotherapy by providing nutrients under metabolic stress (Galluzzi, L., et al., EMBO Journal, 2017). Conversely, impaired expression of these transcripts is linked to the accumulation of toxic protein aggregates in neurodegenerative disorders like Alzheimer's and Parkinson's disease (He, C., & Klionsky, D. J., Annual Review of Genetics, 2009). Therapeutic strategies targeting these mRNAs primarily utilize RNA interference (RNAi) or antisense oligonucleotides (ASOs) to either silence pro-survival autophagy in tumors or potentially modulate autophagic flux in other pathological states (Levine, B., & Kroemer, G., Cell, 2019). While promising, targeting these transcripts poses challenges, including the risk of disrupting basal autophagy, which is necessary for the survival of healthy non-target cells (Mizushima, N., & Komatsu, M., Nature, 2008).
RNA interference (RNAi) or antisense-mediated degradation (RNase H-dependent) of mRNA transcripts to prevent the translation of proteins essential for autophagosome formation and maturation (Levine, B., & Kroemer, G., Cell, 2019).
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Autophagy-related gene messenger RNA (ATG mRNA).